A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Orlando, Florida 32806, United States
St. Petersburg, Florida 33701, United States
Niles, Illinois 60714, United States
Indianapolis, Indiana 46202, United States
Grand Rapids, Michigan 49546, United States
St Louis, Missouri 63110, United States
Philadelphia, Pennsylvania 19107, United States
Knoxville, Tennessee 37920, United States
Memphis, Tennessee 38103, United States
New Lambton, Australia
Jena, Germany
Newcastle upon Tyne, United Kingdom